25 KB109 KB22 KB192920262006Tršinar, Bojanštevilka:115 straniletnik:75str. 697-701ISSN:1318-0347COBISSID:21995225URN:URN:NBN:SI:doc-L9Z5VYCRslSlovensko zdravniško društvoZdravniški vestnikAdrenergic Alpha-AntagonistsAdrenergični alfa-antagonistiDrug TherapyDrug Therapy, CombinationFinasteridFinasteridemotnjeprostataProstata, hiperplazijaprostateProstatic HyperplasiatherapyTreatment OutcomeurologijaZdravilo, terapija sestavljenazdravljenjeZdravljenje, izidKombinirano zdravljenje bolnikov z benigno hiperplazijo prostate| Combination therapy in patients with benign prostatic hyperplasia|Background The purpose of observational program of patients with lower urinarytract symptoms (LUTS) because of benign prostatic hyperplasia (BPH) (LUTS/BPH) was to acquire additional pharmaco-epidemiological data on the safety and efficacy of combination therapy with finasteride and tamsulosin. Methods Observational program of men with BPH was conducted in urological outpatient clinics in Slovenia from April 2004 until November 2005. In open-label, non-interventional program 1173 patients were observed, who had been treated because of LUTS/BPH with com bination therapy with finasteride and tamsulosin, in the framework of common treat meat. At baseline and after six months of treatment for each patient the International Prostatic Symptom Score (IPSS) questionnaire and assessment of quality of life (QL) were filled in. In addition, urinary flow rate and prostate volume were determined. Adverse effects of drugs were reported spontaneously. Forstatistical analysis the Student's t-test was performed. Results Combination therapy with finasteride and tamsulosin was well tolerated. 89 (7.6%) patients discontinuedwith medication because of lack of efficacy or because of adverse effects of drugs. Symptom score, assessment of quality of patients' lives and volume of prostates were significantly lower (p < 0.0001), while urinary flow rate was significantly higher (p < 0.0001) after six months of treatment with finasteride and tamsulosinIzhodišča Namen programa opazovanja bolnikov s težavami z mokrenjem (LUTS - Lower Urinary Tract Symptoms) zaradi benigne hiperplazije prostate (BHP) (LUTS/BHP) je bil pridobiti dodatne farmakoepidemiološke podatke o varnosti inučinkovitosti kombiniranega zdravljenja s finasteridom in tamsulozircom. Metode Program opazovanja moških z diagnosticirano BHP je potekal v uroloških ambulantah po Sloveniji od aprila 2004 do novembra 2005. V odprtem programu sozdravniki v okviru rednega zdravljenja v ambulantah opazovali 1173 bolnikov,pri katerih so se odločili za zdravljenje LUTS/BHP s kombiniranim zdravljenjem s finasteridom 5 mg/dan in tamsulozinom 0,4 mg/dan. Za vsakega opazovanega bolnika so morali izpolniti Mednarodni vprašalnik za točkovno vrednotenje simptomov BHP (IPSS - International Prostatic Symptom Score) in Vprašalrcik o oceni kakovosti življenja (QL) ter izmeriti pretok seča in volumen prostate ob izhodišču in po šestih mesecih zdravljenja. Zabeležiti so morali tudi morebitne neželene učinke zdravljenja. Za statistično analizo podatkov smo uporabili enosmerni Studentov t-test. Rezultati Kombinirano zdravljenje s finasteridom in tamsulozinom so bolniki dobro prenašali. 89 (7,6%) bolnikov je prenehalo jemati zdravila zaradi nezadovoljivega učinka alipa zaradi neželenih učinkov zdravil. Po šestih mesecih zdravljenja s finasteridom in tamsulozinom so bili seštevek točk v vprašalniku IPSS, v vprašalniku QL in volumen prostate značilno nižji (p < 0,0001), pretok seča paznačilno višji (p < 0,0001) v primerjavi z izhodiščnimi vrednostmi. Zaključki Kombinirano zdravljenje bolnikov z LUTS/BHP s finasteridom in tamsulozinom je učinkovito in varnoTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo